Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-582-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Skin sensitization
Overview
In the lubricant additive industry, a common name such as calcium sulfonate or barium sulfonate is used for natural and synthetic long-chain alkylbenzenesulfonic acids, calcium or barium salts. Barium and calcium sulfonates are used as detergents in a broad variety of lubricant applications. Calcium or barium sulfonates with a large excess of calcium or barium carbonate are referred to as high overbased or high total base number (TBN) calcium or barium sulfonates, whereas calcium or barium sulfonates with small amounts of added calcium or barium carbonate are called low overbased or low TBN calcium or barium sulfonates.
Barium sulfonate:
1.In a key study, the dermal sensitisation of this low TBN substance (Benzene, mono-C10-13-alkyl derivs., distn. residues, sulfonated, barium salts, CAS 93820-55-4) was evaluated in a Buehler test in guinea pigs (Smedley, J.W., 2062, according to OECD 406, Table S1). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 250% concentration of the test substance.Following challenge with 25%of the test substancein mineral oil, dermal scores of 1 or 2 were noted in 17/20 test animals and 1/10 challenge control animals at the 24-hour scoring interval. At the 48-hour scoring interval, dermal scores of 1 or 2 were noted in 19/20 test animals and 1/10 challenge control animals. Dermal reactions in the remaining test and challenge control animals were scores of 0 or ±. Group mean dermal scores were higher in the test animals (1.2 to 1.3) as compared to challenge control animals (0.2 to 0.2).The animal test results meet the specifications set in the Guidance on the Application of the CLP Criteria (≥15 % responding at > 20 % topical induction dose, Version 4.1, June 2015), and the data are sufficient for subclassification of the calcium sulfonate test substance (CAS 93820-55-4) into subcategory 1B.
Table S1. Dermal Sensitisation Study (Modified Buehler Design) in Guinea Pigs with a 100% Low TBN Benzene, mono-C10-13-alkyl derivs., distn.residues, sulfonated, barium salts Induction: Challenge Results (Smedley, 2016)
Group
Concentration
Mean Draize Score
# Positive
Conclusion
24 hours
48 hours
Test
25%
1.2
1.3
19/10
Control
25%
0.2
0.2
0/10
Sensitizer
(subcategory 1B)
Control = Topical application of test article to naive animals to account for primary irritation reactions
2.In a key study, the dermal sensitisation of this low TBN substance (Benzene, mono-C10-13-alkyl derivs., distn. residues, sulfonated, barium salts, CAS 93820-55-4) was evaluated in a Buehler test in guinea pigs (A.H.B.M. van Huygevoort, 2012, according to OECD 406, Table S2). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 100% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 100%, were 7/20, and the mean 24/48 hour Draize scores were 0.35/0.15, respectively. The mean 24/48 hour Draize scores for the naïve controls at 1000 were 0/0, respectively. The animal test results meet the specifications set in the Guidance on the Application of the CLP Criteria (≥15 % responding at > 20 % topical induction dose, Version 4.1, June 2015), and the data are sufficient for subclassification of the calcium sulfonate test substance (CAS 93820-55-4) into subcategory 1B.
Table S2. Dermal Sensitisation Study (Modified Buehler Design) in Guinea Pigs with a 100% Low TBN Calcium Sulfonate (Benzene, mono-C10-13-alkyl derivs., distn.residues, sulfonated, barium salts) Induction: Challenge Results (van Huygevoort, 2012)
Group
Concentration
Mean Draize Score
# Positive
Conclusion
24 hours
48 hours
Test
100%
0.35
0.15
07/10
Control
100%
0
0
0/10
Sensitizer
(subcategory 1B)
Control = Topical application of test article to naive animals to account for primary irritation reactions
Calcium sulfonate:
Skin sensitization studies are available for structurally similar natural and synthetic calcium sulfonates. For Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) classification and labelling, EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No 1272/2008 applies. Animal studies show that calcium sulfonates with a TBN greater than 300 are not skin sensitizers, the results in animals at a TBN of 300 exhibit a mixed response, however, human repeat insult patch tests clearly show that high TBN overbased calcium sulfonates (TBN≥300) are not sensitizers (data not shown). Barium sulronate has low TBN and animal test results showed sensitizing potential. However, low TBN calcium sulfonates do not cause sensitization in a substantial number of persons at concentrations of 10% or lower within the definition of sensitisation under EU Regulation (EC) No 1272/2008, more specifically, there are no any TSCA 8(c) allegations of skin sensitization for calcium sulfonates, thus 10% is proposed as the SCL for Calcium sulfonate. The human data is summarized in the following table:
Repeated Insult Patch Test Result Summary
EC#
TBN
Conc
Patch Name
Area
Volume
Amount
Subject
Male
Female
age
Result
939-141-6
10
100%
Webril Cotton Fabric
2cm x 2cm
Assumed 0.2ml
50,000µg/cm2
53
11
42
20-65
some evidence of sensitization but number not given. 44 subjects completed test
939-141-6
10
20%
Webril Cotton Fabric
2cm x 2cm
Assumed 0.2ml
8500µg/cm2
55
11
44
18-66
14 /45
619-278-7 at 10%
10
10%
Parke-Davis Readi-Bandage
2cm x 2cm
0.2ml
4250µg/cm2
159
37
122
18-65
4/154
616-278-7
85
10%
Webril Cotton Fabric
2cmx2cm
Assumed 0.2ml
4250µg/cm2
53
8
45
24-63
positive in 3/48
616-278-7
10
10%
3/4"x3/4" (3.629 cm2)
0.2ml
4685µg/cm2
223
16-70
12/199 at 10%
0% at 1%939-141-6
10
10% or 1%
3/4"x3/4" (3.629 cm2)
0.2ml
10%= 4685µg/cm2;
1%= 425µg/cm2
227
18-75
15/210 @10%,
0/210 at 1%939-141-6
10
10%
Parke-Davis Readi-Bandage
0.2ml
4250µg/cm2
157
28
129
18-65
4/140
263-093-9
30
10/%
Parke-Davis Readi-Bandage
assume 2cm x 2cm
0.2ml
4250µg/cm2
166
26
140
19-68
8/142
263-093-9
30
10% or 1%
3/4"x3/4" (3.629 cm2)
0.2ml
4685µg/cm2
220
19-72
12/205 at 10%
0% at 1%263-093-9
82
10%
2cm x 2cm
Assumed 0.2ml
4250µg/cm2
60
11
49
18-66
0/56
263-093-9
100
10%
2cm x 2cm
0.2g
5000µg/cm2
53
3
50
19-63
0/51
939-141-6
10
1%
Parke-Davis Readi-Bandage
assume 2cm x 2cm
0.2ml
425µg/cm2
53
11
42
18-64
0/48
Low TBN Calcium Sulfonate Skin Sensitisation:
(1) Animal Studies
3.In another key study, the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 10) was evaluated in a Buehler test in guinea pigs (Bonnette, 1993b, according to OECD 406, Table S3). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 50% concentration of the test substance. After approximately one week the animals were re-challenged with a 25% concentration of the test substance. Following the first rechallenge, the animals then were re-challenged with a 10% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 50%, 25%, and 10% were 9/10, 10/10, and 9/10, respectively, and the mean 24/48 hour Draize scores were 1.9/2.1, 1.6/2.0, and 1.5/1.5, respectively. The mean 24/48 hour Draize scores for the naïve controls at 50%, 25%, and 10% were 0.2/0.2, 0.7/0.6, and 0.5/0.5, respectively. The animal test results meet the specifications set in the Guidance on the Application of the CLP Criteria (≥15 % responding at > 20 % topical induction dose, Version 4.1, June 2015), and the data are sufficient for subclassification of the calcium sulfonate test substance (EC 939-141-6) into subcategory 1B.
Table S3. Dermal Sensitisation Study (Modified Buehler Design) in Guinea Pigs with a 100% Low TBN Calcium Sulfonate (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, Calcium Salts; EC 939 -141 -6; TBN = 10) Induction: Challenge Results (Bonnette, 1993b)
Group
Concentration
Mean Draize Score
# Positive
Conclusion
24 hours
48 hours
Test
50%
1.9
2.1
09/10
Sensitizer
(subcategory 1B)
Control
50%
0.2
0.2
1/10
Test
25%
1.6
2.0
10/10
Sensitizer
(subcategory 1B)
Control
25%
0.7
0.6
3/10
Test
10%
1.5
1.5
09/10
Sensitizer
(subcategory 1B)
Control
10%
0.5
0.5
1/10
Control = Topical application of test article to naive animals to account for primary irritation reactions
4.In another key study, the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939 -141 -6; TBN = 10) was evaluated in a Buehler test in guinea pigs (Shults, 1993, according to OECD 406; Table S4). The animals were treated topically with a 100% concentration of the test substance once per week during the three week induction phase. Following a two week rest period, the animals were topically challenged with a 25% concentration of the test substance. After approximately one week the animals were rechallenged with a 10% concentration of the test substance. Following the first rechallenge, the animals then were rechallenged with a 10% concentration of the test substance. The number of animals exhibiting positive sensitisation responses for the test substance at 25%, 10% rechallenge, and 10% second rechallenge were 10/10, 9/10, and 7/10, respectively, and the mean 24/48 hour Draize scores were 1.4/1.15, 0.8/0.95, and 0.8/0.85, respectively. The mean 24/48 hour Draize scores for the naïve controls at 25%, 10% rechallenge, and 10% second rechallenge were 0.8/0.06, 0.55/0.6, and 0.3/0.65, respectively. The animal test results meet the specifications set in the Guidance on the Application of the CLP Criteria (≥15 % responding at > 20 % topical induction dose, Version 4.1, June 2015), and the data are sufficient for subclassification of the calcium sulfonate test substance (EC 939-141-6) into subcategory 1B.
Table S4. Dermal Sensitisation Study (Modified Buehler Design) in Guinea Pigs with a 100% Low TBN Calcium Sulfonate (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, Calcium Salts; EC 939 -141 -6; TBN = 10) Induction: Challenge Results (Shults, 1993)
Group
Concentration
Mean Draize Score
# Positive
Conclusion
24 hours
48 hours
Test
25%
1.4
1.15
10/10
Sensitizer
(subcategory 1B)
Control
25%
0.8
0.06
6/10
Test
10%
0.8
0.95
09/10
Sensitizer
(subcategory 1B)
Control
10%
0.55
0.6
3/10
Test
10%
0.8
0.85
07/10
Sensitizer
(subcategory 1B)
Control
10%
0.3
0.65
3/10
Control = Topical application of test article to naive animals to account for primary irritation reactions
5.In a key study, the dermal sensitisation of a low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 10) was evaluated in the local lymph node assay (LLNA) (Lees, 1996, according to OECD 429). Groups of male mice (4/group) were dose with approximately 25 µL of 0.1, 1, 10 or 30% concentrations of the test material in DMF on the dorsal surface of each ear for three consecutive days. The animals were then injected with 3H-methylthymidine, and the auricular lymph nodes where then collected and prepared for scintillation counting. A three-fold or greater increase in isotope incorporation was observed at all test concentrations (subcategory 1A). The positive response in this study is supportive of the sensitisation response for low TBN calcium sulfonates noted in other sensitisation studies. . However, this substance is surface active, literature data have shown limitations in LLNA for predicting skin sensitization potential of surfactants and their intermediates.
(2) Human Data
1.In another key study, the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN =10) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1993a; Table S5). A panel of 53 subjects was identified for this test. In the induction phase the undiluted (100% concentration) test substance was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 44 subjects that completed the induction phase was topically challenged with the undiluted (100% concentration) test substance. Positive responses (scores≥1) were observed in 9/44 and 6/44 at the 24 and 72 hour readings, respectively. Rechallenge of the six subjects suspected of exhibiting allergic reactions confirmed allergic contact dermatitis in four (4/44 or 9%). In the present study an induction dose per unit area of 50,000 µg/cm² is assumed as the pure substance (100%) was used for exposure of a skin area of 4 cm² (“A sufficient quantity of the calcium sulfonate test article was applied directly to the skin with a cotton-tip applicator. In addition, a thin layer was also placed onto a 2 cm x 2 cm square of Webril cotton fabric affixed to Scanpor (Allerderm) semi-occlusive surgical tape which was applied to the back of each subject, between the scapulae and waist, adjacent to the spinal mid-line.”), which leads to classification of the calcium sulfonate test substance (EC 939-141-6) as a sensitizer (subcategory 1B).
2.In another key study, the dermal sensitisation of this low TBN substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN = 10) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994c, Table S5). A panel of 55 subjects was identified for this test. In the induction phase a 20% concentration of the test substance in mineral oil was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 45 subjects that completed the induction phase was topically challenged with a 20% concentration of the test substance in mineral oil. Positive responses (scores ≥ 1) were observed in 16/45 and 16/45 at the 24 and 72 hour readings (or 48 or 96 hour make up readings), respectively. Approximately 31 % (14/45) of the test population exhibited skin reactivity patterns that were suggestive or indicative of low to moderate grade, induced allergic contact dermatitis. In the present study an induction dose per unit area of 8500 µg/cm² is assumed as a dilution of the pure substance (20%) was used for exposure of a skin area of 4 cm² (“A sufficient quantity of the calcium sulfonate test article to cover the test site was applied directly to the skin with a cotton-tipped applicator. In addition, a thin layer was placed onto a 2 cm x 2 cm square of Webril cotton fabric affixed to Scanpor (Allerderm) semi-occlusive surgical tape which was applied to the back of each subject, between the scapulae and waist, adjacent to the spinal mid-line.”), which leads to classification of the calcium sulfonate test substance (EC 939-141-6) as a sensitizer (subcategory 1B).
Table S5. Human Repeat Insult Patch Tests (HRIPT) with a Low TBN Calcium Sulfonate (Benzenesulfonic Acid, 4-(Mono-C15-36 Branched Alkyl Derivs., C24 Rich) and Benzenesulfonic Acid, 4-Octadecyl, Calcium Salts; EC 939-141-6; TBN = 10): Challenge Results (Shanahan & Erianne, 1993a; Shanahan & Erianne, 1994c)
Test Phase
Concentration
# Positive Responses
Conclusion
Reference
24 hours
72 hours
Induction
100%
Challenge
100%
09/44
06/44
Rechallenge
100%
Observed up to 96h
04/44
Sensitizer
(subcategory 1B)
Shanahan & Erianne, 1993a
Induction
20%
Challenge
20%
16/45*
16/45*
Sensitizer
(subcategory 1B)
Shanahan & Erianne, 1994c
* 48 or 96 hour make-up readings were required for some subjects.
Low TBN Specific Concentration Limit (SCL):
The weight-of-evidence of all the animal and human studies demonstrates that low TBN calcium sulfonates are skin sensitizers. However, well-conducted, reliable, controlled HRIPT studies show that these substances do not cause sensitisation in a substantial number of subjects at concentrations of 10% and lower.
3.In another key study, the dermal sensitisation of a low TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; CAS 75975-85-8; EC 616-278-7; TBN = 10) was evaluated in a human repeat insult patch test (Alworth, Schwartz & Erianne, 1995a; Table S6). Five panels consisting of a total of 159 subjects were identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 154 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 4/154 (2.6%) of the subjects exhibited sensitisation responses. Based on the testing protocol: 0.2 mL of 10% solution was used for exposure of a skin area of 4 cm² for induction and challenge (“A sufficient amount of the calcium sulfonate test article (approximately 0.2 mL) was placed onto a Parke-Davis ReadiBandage occlusive patch, which was applied to the back of each subject between the scapulae and waist, adjacent to the spinal mid-line.”), an induction dose per unit area of 4250 µg/cm² was derived which leads to classification of the calcium sulfonate test substance (CAS 75975-85-8) as a sensitizer (subcategory 1B).
4.In another key study, the dermal sensitisation of a low TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; CAS 75975-85-8; EC 616-278-7; TBN = 85), was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994a; Table S6). A panel of 53 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 48 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 3/48 (6.3%) of the subjects exhibited sensitisation responses. Based on the testing protocol: 0.2 mL of 10% solution was used for exposure of a skin area of 4.0 cm² for induction and challenge, an induction dose per unit area of 4250 µg/cm² was derived for induction and challenge. (“A sufficient quantity of the calcium sulfonate test article to cover the test site was applied directly to the skin with a cotton-tipped applicator. In addition, a thin layer was placed onto a 2 cm x 2 cm square of Webril cotton fabric affixed to Scanpor (Allerderm) semi-occlusive surgical tape which was applied to the back of each subject, between the scapulae and waist, adjacent to the spinal mid-line.”), which leads to classification of the calcium sulfonate test substance (CAS 75975-85-8) as a sensitizer (subcategory 1B).
5. In another key study, the dermal sensitisation of a low TBN analogue of this substance (Benzene, polypropene derivs., sulfonated, calcium salts; CAS 75975-85-8; EC 616-278-7; TBN = 10) was evaluated in a human repeat insult patch test (Eisenberg, 1994a; Table S6). A panel of 223 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 199 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 12/199 (6.0%) of the subjects exhibited sensitisation responses following the 10% challenge Based on the testing protocol: 0.2 mL of 10% solution) was used for exposure of a skin area of 3.629 cm² for induction and challenge (“Prior to the initiation of this study, the calcium sulfonate test material was prepared as a 10% solution using white mineral oil as a diluent. Approximately 0.2 mL of the calcium sulfonate test material was applied to the 3/4" x 3/4" gauze portion of an adhesive dressing. This was then applied to the appropriate treatment site to form an occluded patch.”), an induction dose per unit area of 4685 µg/cm² was derived, which leads to classification of the calcium sulfonate test substance (CAS 75975-85-8) as a sensitizer (subcategory 1B). A total of 0/199 (0%) of the subjects exhibited sensitisation responses following the 1% challenge.
6.In another key study, the dermal sensitisation of this substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN =10) was evaluated in a human repeat insult patch test (Eisenberg,1994b; Table S6). A panel of 227 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 210 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 15/200 (7.1%) of the subjects exhibited sensitisation responses following the 10% challenge. Based on the testing protocol: 0.2 mL of 10% solution was used for exposure of a skin area of 3.629 cm² for induction and challenge. (“Prior to the initiation of this study, the calcium sulfonate test material was prepared as a 10% solution using white mineral oil as a diluent. Approximately 0.2 mL of the calcium sulfonate test material was applied to the 3/4" x 3/4" gauze portion of an adhesive dressing. This was then applied to the appropriate treatment site to form an occluded patch.”), an induction dose per unit area of 4685 µg/cm² was derived, which leads to classification of the calcium sulfonate test substance (EC 939-141-6) as a sensitizer (subcategory 1B).
7.In another key study, the dermal sensitisation of this substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; EC 939-141-6; TBN =10) was evaluated in a human repeat insult patch test (Alworth, Schwartz & Erianne, 1995b; Table S6). Four panels consisting of a total of 157 subjects were identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 140 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 4/140 (2.9%) of the subjects exhibited sensitisation responses. Based on the testing protocol: 0.2 mL of 10% solution was used for exposure of a skin area of 4.0 cm² for induction and challenge, an induction dose per unit area of 4250 µg/cm² was derived for induction and challenge (“A sufficient amount of the calcium sulfonate test article (approximately 0.2 mL) was placed onto a Parke-Davis ReadiBandage occlusive patch, which was applied to the back of each subject between the scapulae and waist, adjacent to the spinal mid-line.”), which leads to classification of the calcium sulfonate test substance (EC 939-141-6) as a sensitizer (subcategory 1B).
8.In another key study, the dermal sensitisation of a low TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; CAS 61789-86-4; EC 263-093-9; TBN = 30) was evaluated in a human repeat insult patch test (Alworth, Schwartz & Erianne, 1995c; Table S6). Five panels consisting of a total of 166 subjects were identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 142 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 8/142 (5.6%) of the subjects exhibited sensitisation responses. Based on the testing protocol: 10% dilutions sample; sufficient amount of the calcium sulfonate test article (approximately 0.2 mL) was placed onto a Parke-Davis ReadiBandage occlusive patch, which was applied to the back of each subject between the scapulae and waist. adjacent to the spinal mid-line, an induction dose per unit area of 4250 µg/cm² was derived, which leads to classification of the calcium sulfonate test substance (CAS 61789-86-4) as a sensitizer (subcategory 1B).
9. In another key study, the dermal sensitisation of a low TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; CAS 61789-86-4; EC 263-093-9; TBN = 30) was evaluated in a human repeat insult patch test (Eisenberg, 1994c; Table S6). A panel of 220 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of ten applications. Following a two week rest period, each of the 205 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 12/205 (ca. 5.9%) of the subjects exhibited sensitisation responses following the 10% challenge. Based on the testing protocol: 0.2 mL of 10% solution was used for exposure of a skin area of 3.629 cm² for induction and challenge (“Prior to the initiation of this study, the calcium sulfonate test material was prepared as a 10% solution using white mineral oil as a diluent. Approximately 0.2 mL of the calcium sulfonate test material was applied to the 3/4" x 3/4" gauze portion of an adhesive dressing. This was then applied to the appropriate treatment site to form an occluded patch.”), an induction dose per unit area of 4685µg/cm² was derived, which leads to classification of the calcium sulfonate test substance (CAS 61789-86-4) as a sensitizer (subcategory 1B). A total of 0/205 (ca. 0%) of the subjects exhibited sensitisation responses following the 1% challenge.
10.In another key study, the dermal sensitisation of a low TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; CAS 61789-86-4; , EC 263-093-9; TBN = 82, was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994e; Table S6). A panel of 60 subjects was identified for this test. In the induction phase a 10% concentration of the test substance in mineral oil was administered to a 2cm x 2cm gauze portion (4250 µg/cm² was derived), and directly applied to the skin and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 56 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 0/56 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
11. In another key study, the dermal sensitisation of a low TBN analogue of this substance (Sulfonic acids, petroleum, calcium salts; CAS 61789-86-4; EC 263-093-9; TBN = 100) was evaluated in a human repeat insult patch test (Shanahan & Erianne, 1994f; Table S6). A panel of 53 subjects was identified for this test. In the induction phase 0.2g of 10% concentration of the test substance in mineral oil was administered directly to the skin (2 cm x 2 cm gauze portion, 5000 µg/cm² was derived) and covered with a semi-occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 51 subjects that completed the induction phase was topically challenged with a 10% concentration of the test substance in mineral oil. A total of 0/51 (0.0%) of the subjects exhibited sensitisation responses. Based on these results the test substance was determined to not cause a sensitisation response.
Table S6. Calcium Sulfonate Human Repeat Insult Patch Tests (HRIPT) with a 10% Induction Phase Concentration
Substance
Challenge %
Challenge Response
Sensitization Response (%)
Conclusion
Reference
EC 616-278-7 (TBN = 10)
10%
2/154 with mild to moderate erythema with moderate papular reactions;
2/154 with mild to marked erythema and with moderate oedema and moderate papular reactions in the induction phase that were considered sensitised and, therefore were not challenged
4/154
(2.6%)
Sensitizer (subcategory 1B)
Alworth, Schwartz & Erianne, 1995a
EC 616-278-7CAS 75975-85-8;(TBN = 85)
10%
2/48 with mild to moderate erythema
1/48 with moderate oedema and papular that spread beyond contact site during induction were not challenged
3/48
(6.3%)
Sensitizer (subcategory 1B)
Shanahan & Erianne, 1994a
EC 616-278-7 (TBN = 10)
10%
6/199 with mild erythema @ original sites;
5/199 with moderate erythema original site;
1/199 with moderate erythema virgin site
12/199
(6.0%)
Sensitizer (subcategory 1B)
Eisenberg, 1994a
EC 939-141-6 (TBN = 10)
10%
1/210 with mild erythema original and virgin site;
6/210 with BP to mild erythema original site;
5/210 moderate erythema original site; 1/210 with marked erythema original site;
1/210 with mild erythema virgin site; 1/210 with marked erythema original site
15/210
(7.1%)
Sensitizer (subcategory 1B)
Eisenberg, 1994b
EC 939-141-6 (TBN = 10)
10%
3/140 with mild to moderate erythema with mild to moderate oedema and/or mild to severe papular reactions in some;
1/140 with moderate erythema with mild to severe papular reaction including an adverse reaction report of reaction spreading to back/neck @ 96 hrs with erythema deminishing @ 192 hours but papular reaction spreading to the eyes
4/140
(2.9%)
Sensitizer (subcategory 1B)
Alworth, Schwartz & Erianne, 1995b
EC 263-093-9 (TBN = 30)
10%
7/142 with mild to moderate erythema/oedema including mild to moderate papular reactions;
1/142 with moderate erythema @ 24 hours and severe erythema @ 72 hours
8/142
(5.6%)
Sensitizer (subcategory 1B)
Alworth, Schwartz & Erianne, 1995c
EC 263-093-9 (TBN = 30)
10%
3/205 with mild erythema @ original & virgin sites;
1/205 with moderate erythema @ both areas;
7/205 with mild erythema original site;
1/205 with mild erythema virgin site
12/205
(5.8%)
Sensitizer (subcategory 1B)
Eisenberg, 1994c
CAS 61789-86-4; EC 263-093-9 (TBN = 82)
10%
56/56 no reaction
0/56
(0%)
Not a sensitizer
Shanahan & Erianne, 1994e
CAS 61789-86-4; EC 263-093-9 (TBN = 100)
10%
51/51 no reaction
0/51
(0%)
Not a sensitizer
Shanahan & Erianne, 1994f
CAS 61789-86-4; EC 263-093-9 = Sulfonic acids, petroleum, calcium salts
CAS 75975-85-8; EC 616-278-7 = Benzene, polypropene derivs., sulfonated, calcium salts
EC 939-141-6 =Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts12.In another key study, the dermal sensitisation of an analogue of this substance (Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts; , EC 939-141-6; TBN = 10) was evaluated in a human repeat insult patch test (DiFiglia, Shanahan & Erianne, 1993b). A panel of 53 subjects was identified for this test. In the induction phase a 1% concentration of the test substance in mineral oil was administered directly to the skin and covered with an occlusive patch three times per week for a total of nine applications. Following a two week rest period, each of the 48 subjects that completed the induction phase was topically challenged with 0.2 ml of 1% concentration of the test substance in mineral oil. A total of 0/48 (0%) of the subjects exhibited sensitisation responses following the 1% challenge. Based on these results the test substance was determined not to induce irritation or sensitisation at 1%.
In accordance with EU CLP Regulation (EC) No 1272/2008, classification of low TBN calcium sulfonates is required for sensitisation (subcategory 1B) with a specific concentration limit of 10%. This also applies to low TBN barium sulfonates.
Conclusion
The weight-of-evidence indicates that low TBN calcium and barium sulfonates (TBN < 300) are skin sensitizers with a specific concentration limit (SCL) of 10%. Studies in guinea pigs and human volunteers show that low TBN Benzenesulfonic acid, 4-(mono-C15 -36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts (EC 939-141-6; TBN = 13) are skin sensitizers. Numerous well-conducted, reliable, controlled human (HRIPT) studies with benzene, polypropene derivs., sulfonated, calcium salts (EC 616-278-7; TBN values ranging from 13 to 85), sulfonic acids, petroleum, calcium salts (CAS 61789-86-4; EC 263-093-9; TBN = 30 to 100), and Benzenesulfonic acid, 4-(mono-C15-36 branched alkyl derivs., C24 rich) and Benzenesulfonic acid, 4-octadecyl, calcium salts (EC 939-141-6; TBN = 13) show that low TBN calcium sulfonates do not cause sensitisation in a substantial number of subjects at concentrations of 10% and lower.
In accordance with EU CLP Regulation (EC) No 1272/2008, classification (subcategory 1B) is required for low TBN calcium and barium sulfonates (TBN < 300) with a specific concentration limit of 10%.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The classification and labelling for Benzene, mono-C10-13-alkyl derivs., distn. residues, sulfonated, barium salts (generic name: C10 -13 barium sulfonate) is based on the results of numerous skin sensitisation animal studies with low and high TBN calcium sulfonates. Results of Human Repeat Insult Test (HRIPT) with low and high TBN calcium sulfonates have also been taken into account (please also refer to the respective section of the CSR).
In accordance with Regulation (EC) No 1272/2008 (CLP Regulation), classification (subcategory 1B) is required for low TBN calcium and barium sulfonates (TBN < 300) with a specific concentration limit of 10%.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.